(0.38%) 5 207.44 points
(0.66%) 39 313 points
(0.28%) 16 348 points
(0.15%) $79.11
(4.34%) $2.28
(0.78%) $2 340.40
(2.76%) $28.36
(0.78%) $992.25
(-0.25%) $0.928
(-0.27%) $10.86
(-0.18%) $0.799
(0.89%) $92.56
-1.83% INR 1 115.30
Live Chart Being Loaded With Signals
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India...
Stats | |
---|---|
Today's Volume | 1.44M |
Average Volume | 2.04M |
Market Cap | 653.50B |
EPS | INR0 ( 2024-02-11 ) |
Next earnings date | ( INR14.00 ) 2024-05-25 |
Last Dividend | INR3.00 ( 2023-02-17 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 23.62 |
ATR14 | INR1.304 (0.12%) |
Volume Correlation
Aurobindo Pharma Limited Correlation
10 Most Positive Correlations | |
---|---|
SETF10GILT.NS | 0.946 |
IZMO.NS | 0.936 |
ADORWELD.NS | 0.933 |
ANMOL.NS | 0.927 |
GTNTEX.NS | 0.92 |
ANURAS.NS | 0.918 |
FOCUS.NS | 0.918 |
TIIL.NS | 0.917 |
GISOLUTION.NS | 0.914 |
KIRLOSIND.NS | 0.913 |
10 Most Negative Correlations | |
---|---|
STARTECK.NS | -0.883 |
GENESYS.NS | -0.878 |
EASTSILK.NS | -0.871 |
SEYAIND.NS | -0.871 |
ORTINLAB.NS | -0.864 |
DEEPINDS.NS | -0.862 |
GRMOVER.NS | -0.859 |
KOHINOOR.NS | -0.856 |
CLNINDIA.NS | -0.853 |
ESABINDIA.NS | -0.852 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aurobindo Pharma Limited Correlation - Currency/Commodity
Aurobindo Pharma Limited Financials
Annual | 2022 |
Revenue: | INR246.17B |
Gross Profit: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Revenue: | INR246.17B |
Gross Profit: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Revenue: | INR233.67B |
Gross Profit: | INR132.26B (56.60 %) |
EPS: | INR45.19 |
FY | 2021 |
Revenue: | INR245.58B |
Gross Profit: | INR146.55B (59.68 %) |
EPS: | INR91.05 |
Financial Reports:
No articles found.
Aurobindo Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR3.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2001-09-12 |
Last Dividend | INR3.00 | 2023-02-17 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | INR38.23 | -- |
Avg. Dividend % Per Year | 0.47% | -- |
Score | 2.7 | -- |
Div. Sustainability Score | 4.12 | |
Div.Growth Potential Score | 3.15 | |
Div. Directional Score | 3.63 | -- |
Year | Amount | Yield |
---|---|---|
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.25 | 0.36% |
2019 | INR2.50 | 0.34% |
2020 | INR4.25 | 0.93% |
2021 | INR4.50 | 0.49% |
2022 | INR6.00 | 0.82% |
2023 | INR3.00 | 0.69% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SWARAJENG.NS | Dividend Knight | 2023-07-06 | Annually | 23 | 2.81% | |
NDRAUTO.NS | Dividend Junior | 2023-07-12 | Annually | 4 | 0.59% | |
ICICIGI.NS | Dividend Junior | 2023-06-12 | Annually | 8 | 0.36% | |
CENTENKA.NS | Dividend Junior | 2023-08-11 | Annually | 22 | 1.85% | |
RUPA.NS | Dividend Junior | 2023-08-01 | Annually | 13 | 0.60% | |
LINCOLN.NS | Dividend Junior | 2023-09-15 | Annually | 9 | 0.32% | |
GEECEE.NS | Dividend Junior | 2023-09-08 | Sporadic | 18 | 0.97% | |
ARIHANTCAP.NS | Dividend Junior | 2023-07-28 | Annually | 4 | 0.39% | |
TFCILTD.NS | Dividend Junior | 2023-08-11 | Annually | 23 | 1.38% | |
ORICONENT.NS | Dividend Junior | 2023-09-13 | Annually | 10 | 1.41% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.100 | 1.500 | 7.99 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 15.99 | 1.000 | 5.19 | 5.19 | [3 - 30] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.548 | 1.000 | 4.20 | 4.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.148 | 1.000 | 9.03 | 9.03 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.19 | 1.000 | 7.66 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 1.474 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.393 | 1.500 | 0.164 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.417 | 1.500 | -6.11 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.79 | 0 | [0.1 - 0.5] |
Total Score | 3.15 |
Aurobindo Pharma Limited
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators